Literature DB >> 2013979

Philadelphia positive acute lymphoblastic leukemia in adults: age distribution, BCR breakpoint and prognostic significance.

L M Secker-Walker1, J M Craig, J M Hawkins, A V Hoffbrand.   

Abstract

Clonal karyotype, clinical and blast cell features were established in 113 adults, aged 15-68 (mean 31.2) years with acute lymphoblastic leukemia (ALL). The karyotypes were: Philadelphia positive (Ph+), 23 cases; t(4;11), six cases; other chromosome findings (group II), 84 cases. Ph+ patients were older (mean 39.7 years) at presentation than the group II patients (mean 28.3 years) (p less than 0.0001). Ph+ was less frequent than expected in teenagers (15-20 years) (10.3%) and patients aged 21-50 years (21.8%), and more frequent in patients over 50 years old (43.8%) (p less than 0.01). Follow-up (between 0.5 and 4.5 years) was obtained for 108 patients. Age and karyotype (Ph+ versus group II) were prognostically significant for event-free (EFS) and overall survival (S) (p less than 0.001 in each instance). Ph+ patients fared worse than group II cases in all age groups, but karyotype added prognostic significance to age only when Ph+ and t(4;11) cases were combined (group I) (group I versus group II: EFS, p = 0.054; S, p = 0.043). The Ph breakpoint location M-bcr+ (nine cases) and M-bcr- (14 cases) was irrelevant to age (mean 37.7 and 41.3, respectively) and to prognosis. The findings indicate a fundamental difference between the genetics of ALL in most older and the majority of younger patients which may partly explain the increasingly poor prognosis with age.

Entities:  

Mesh:

Year:  1991        PMID: 2013979

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  28 in total

1.  Acute lymphoblastic leukemia with t(1;9;22)(q32;q34;q11).

Authors:  Shin Fujisawa; Heiwa Kanamori; Maki Takabayashi; Masatsugu Tanaka; Satoshi Yamaji; Naoto Tomita; Katsumichi Fujimaki; Yoshiaki Ishigatsubo
Journal:  Int J Hematol       Date:  2002-05       Impact factor: 2.490

Review 2.  Philadelphia-positive acute lymphoblastic leukemia: current treatment options.

Authors:  Theresa Liu-Dumlao; Hagop Kantarjian; Deborah A Thomas; Susan O'Brien; Farhad Ravandi
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

3.  Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  Adele K Fielding
Journal:  Haematologica       Date:  2010-01       Impact factor: 9.941

4.  10-year complete remission in a Philadelphia chromosome-positive acute lymphoblastic leukemia patient using imatinib without high-intensity chemotherapy or allogeneic stem cell transplantation.

Authors:  Katsumichi Fujimaki; Yukako Hattori; Hideaki Nakajima
Journal:  Int J Hematol       Date:  2017-11-29       Impact factor: 2.490

5.  Outcome of Philadelphia Positive Acute Lymphoblastic Leukemia With or Without Allogeneic Stem Cell Transplantation in a Retrospective Study.

Authors:  Narendra Agrawal; Priyanka Verma; Neha Yadav; Rayaz Ahmed; Pallavi Mehta; Priyanka Soni; Shinto Francis; Dinesh Bhurani
Journal:  Indian J Hematol Blood Transfus       Date:  2018-09-01       Impact factor: 0.900

Review 6.  Treatment of Philadelphia Chromosome-Positive Acute Lymphocytic Leukemia.

Authors:  Aaron Ronson; Ariella Tvito; Jacob M Rowe
Journal:  Curr Treat Options Oncol       Date:  2017-03

7.  Phase II trial of hyper CVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia.

Authors:  Ohad Benjamini; Theresa Liu Dumlao; Hagop Kantarjian; Susan O'Brien; Guillermo Garcia-Manero; Stefan Faderl; Jeffrey Jorgensen; Rajyalakshmi Luthra; Rebecca Garris; Deborah Thomas; Partow Kebriaei; Richard Champlin; Elias Jabbour; Jan Burger; Jorge Cortes; Farhad Ravandi
Journal:  Am J Hematol       Date:  2014-03       Impact factor: 10.047

8.  Treatment outcomes of adolescent acute lymphoblastic leukemia treated on Tokyo Children's Cancer Study Group (TCCSG) clinical trials.

Authors:  Motohiro Kato; Atsushi Manabe; Katsuyoshi Koh; Takeshi Inukai; Nobutaka Kiyokawa; Takashi Fukushima; Hiroaki Goto; Daisuke Hasegawa; Chitose Ogawa; Kazutoshi Koike; Setsuo Ota; Yasushi Noguchi; Akira Kikuchi; Masahiro Tsuchida; Akira Ohara
Journal:  Int J Hematol       Date:  2014-06-18       Impact factor: 2.490

Review 9.  Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia.

Authors:  A K Fielding; G A Zakout
Journal:  Curr Hematol Malig Rep       Date:  2013-06       Impact factor: 3.952

10.  Acute lymphoblastic leukemia in patients over 59 years of age. Experience in a single center over a 10-year period.

Authors:  E Späth-Schwalbe; G Heil; H Heimpel
Journal:  Ann Hematol       Date:  1994-12       Impact factor: 3.673

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.